MedTrace Logo

Semaglutide in Treatment of Obesity

NCT06604624 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2026-04-06

No results posted yet for this study

Summary

This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

Conditions

Interventions

DRUG

HD1916

HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

DRUG

semaglutide

semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

Sponsors & Collaborators

  • CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2025-08-27
Completion
2025-09-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604624 on ClinicalTrials.gov